Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Multicentre Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

NCT03427073 is registered in ClinicalTrials.gov with Almac Discovery as lead sponsor.

NCT NCT03427073
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03427073 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Multicentre Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
Lead sponsor
Almac Discovery
Phase
Phase 1
Overall status
Terminated
Start date
April 27, 2015
Completion date
March 13, 2017
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, solid tumors